Diop Saliou, Moulin Charline, Aïssatou Touré Sokhna, Gueye Serigne Mourtalla, Deltour Sabine, Diop Yankhoba, Ndiaye Fatou Samba, Dial Mouhamadou Cherif, Sartelet Hervé, Seck Moussa, Fall Seynabou, Senghor Alioune Badara, Touré Awa Oumar, Faye Blaise Felix, Bousso Elimane Seydi, Diallo Alioune Badara, Keita Mohamed, Niang Elhadji Daouda, Dieng Nata, Vigneron Jean, Thieblemont Catherine, Lévy Vincent, Raphael Martine, Feugier Pierre
Department of Hematology University of Cheikh Anta Diop Dakar Senegal.
Department of Hematology Nancy University Hospital Vandoeuvre-lès-Nancy Nancy France.
EJHaem. 2025 Aug 12;6(4):e70133. doi: 10.1002/jha2.70133. eCollection 2025 Aug.
Management of diffuse large B-cell lymphoma (DLBCL) in Africa is hampered by limited access to diagnosis and treatment, due to the small number of haematopathologists and lack of clear healthcare pathway. A cooperation between France and Senegal was established to improve diagnosis and provide access to the standard-of-care (R-CHOP) to patients with DLBCL in Dakar.
Surgical biopsies were examined in Senegal, then through the Internet Pathology Suite platform, and, when needed, further studied in France. A diagnosis was thus reached for 65/70 biopsies from adults with suspected lymphoma, including 31 DLBCL. A total of 30 patients entered a pilot treatment of six cures of R-CHOP, follow-up and support therapy, between July 2018 and May 2022. The overall response rate was 73% with 57% of complete responses. With a median follow-up of 11.4 months, 24-month overall and progression-free survival rates are of 80% (95% CI 58-91) and 74% (95% CI 50-88). Grade 3/4 haematological toxicity was reported in 20% of the cases.
This study brings the proof-of-concept that an accurate DLBCL diagnosis can be obtained in Senegal with organized support and that R-CHOP therapy can be properly conducted, yielding the expected efficacy with acceptable safety.
SEN18/11.
在非洲，由于血液病理学家数量少且缺乏明确的医疗保健途径，弥漫性大B细胞淋巴瘤（DLBCL）的管理受到诊断和治疗机会有限的阻碍。法国和塞内加尔建立了合作关系，以改善达喀尔DLBCL患者的诊断并提供标准治疗（R-CHOP）。
在塞内加尔对手术活检样本进行检查，然后通过互联网病理套件平台进行检查，必要时在法国进行进一步研究。因此，对70例疑似淋巴瘤成人患者的活检样本中的65例做出了诊断，其中包括31例DLBCL。在2018年7月至2022年5月期间，共有30名患者接受了六周期R-CHOP的试验性治疗、随访和支持治疗。总体缓解率为73%，完全缓解率为57%。中位随访时间为11.4个月，24个月的总生存率和无进展生存率分别为80%（95%CI 58-91）和74%（95%CI 50-88）。20%的病例报告了3/4级血液学毒性。
本研究提供了概念验证，即在有组织的支持下，塞内加尔可以获得准确的DLBCL诊断，并且可以正确实施R-CHOP治疗，产生预期疗效且安全性可接受。
SEN18/11
